Drug Profile
Research programme: inflammation and cancer therapeutics - Ampio Pharmaceuticals
Alternative Names: NCE-001; Para-phenoxy-methylphenidate - Ampio PharmaceuticalsLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Ampio Pharmaceuticals
- Developer Ampio Pharmaceuticals; Syngene
- Class Anti-inflammatories; Antineoplastics; Phenylacetates; Piperazines; Piperidines; Small molecules
- Mechanism of Action Protein phosphatase 2A stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glioblastoma; Inflammation; Inflammatory breast cancer; Neuroblastoma; Renal cell carcinoma
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Neuroblastoma in USA
- 28 Mar 2020 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 28 Mar 2020 No recent reports of development identified for preclinical development in Inflammatory breast cancer in USA